Cambridge Investment Research Advisors, Inc. Cardiol Therapeutics Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 321,285 shares of CRDL stock, worth $350,200. This represents 0.0% of its overall portfolio holdings.
Number of Shares
321,285
Previous 330,505
2.79%
Holding current value
$350,200
Previous $424,000
26.89%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CRDL
# of Institutions
43Shares Held
7.63MCall Options Held
4.9KPut Options Held
3.8K-
Tejara Capital LTD London, X03.12MShares$3.4 Million2.61% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD882KShares$961,9110.23% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9796KShares$867,2310.31% of portfolio
-
Pvg Asset Management Corp Golden, CO487KShares$531,1513.54% of portfolio
-
Lion Street Advisors, LLC334KShares$363,7600.11% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $67.5M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...